News and Announcements
Crowd Mobile Reports Record Fourth Quarter with $11.6m in Revenue & $3.3 EBITDA
- Published July 18, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Crowd Mobile Limited (ASX: CM8) has recently announced the Fourth Quarter results for the three months ended 30 June 2017. Record quarterly revenue has supported the company’s strong FY17 performance.
KEY TAKEAWAYS:
- Revenue of $11.6 million
- Underlying EBITDA of $3.3 million
- Strong Positive Underlying Operating cash flow of $2.2 million
- Net Debt of $2.7 million
Crowd Mobile’s Chief Executive Officer, Domenic Carosa: “Crowd Mobile is delighted to finish a successful 2017 financial year with a record fourth quarter. Over the quarter our Revenue at $11.6 million, Underlying EBITDA of $3.3 million and Underlying Operating Cash Flow have grown strongly from the prior quarter.
Over the year our Q&A business has enjoyed another stellar year, growing 58% in message volumes from the prior year, which continues a very consistent cumulative growth rate since going public. Crowd Mobile’s Net Debt has been reduced by more than 80% in FY17 and the Company is committed to transitioning to a net cash position in FY18.
Crowd Mobile will continue to focus on organically growing its core businesses while creating new revenue streams from our Digital Influencer business (Crowd Media) and we look forward to updating shareholders with material developments as they occur.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
